Scholar Rock Holding Corporation (SRRK)
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Scholar Rock Q1 Earnings Call Highlights
Scholar Rock NASDAQ: SRRK said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company's investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026.
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating
I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power.
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
